Skip to main content
. Author manuscript; available in PMC: 2015 Feb 5.
Published in final edited form as: Breast Cancer Res Treat. 2014 Feb 22;144(2):287–298. doi: 10.1007/s10549-014-2877-y

Table 1.

IC50 values (3 day treatment) for MLN0128 and TSA as single agents in breast cancer cells and non-transformed mammary epithelial cells

Cell Line ER PR HER2 PIK3CA PTEN protein expression/mutation MLN0128 IC50 (nM) TSA IC50 (nM)
SKBR3 − − + WT +/WT 4.36 30.9
MDA-MB-231 − − − WT ++++/WT 11.0 93.3
MCF7 + + − E545K +++/WT 11.8 60.3
MCF7/HER2-18 + + + E545K +++/WT 18.6 >100
BT-474 − + + WT ++++/WT >25.0 93.9
MCF-10A − − − WT +++/WT 24.5 >100

IC50 values were calculated for MLN0128 and TSA from each cell line following a 72 h cell viability assay. Values were calculated from at least six independent wells from two independent experiments. Overexpression status for ER, PR, and HER2 is indicated along with PIK3CA mutation status and PTEN loss